Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: | Completed |
---|---|
Conditions: | Alzheimer Disease, Cognitive Studies, Neurology |
Therapuetic Areas: | Neurology, Psychiatry / Psychology |
Healthy: | No |
Age Range: | 60 - 90 |
Updated: | 5/3/2014 |
Start Date: | December 2010 |
End Date: | June 2013 |
Contact: | KC Fadem |
Email: | kfadem@neuronnetrix.com |
Phone: | 502-561-9040 |
The proposed study is designed to evaluate the performance of the COGNISION™ System as a
tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical
settings. The design of this study is guided by two overriding factors: 1) to optimize
the performance of the event related potentials (ERP) classifiers, the subjects making up
the training sets must be well characterized as to their clinical diagnosis, and 2) all ERP
tests must be performed and reproduced in real-world clinical settings.
tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical
settings. The design of this study is guided by two overriding factors: 1) to optimize
the performance of the event related potentials (ERP) classifiers, the subjects making up
the training sets must be well characterized as to their clinical diagnosis, and 2) all ERP
tests must be performed and reproduced in real-world clinical settings.
The study will be :
A. Multi-Center Study:
primary goal of this study will be to evaluate the COGNISION™ Platform across multiple study
locations. This will demonstrate an ability to perform tests, collect data, and generate
classifications irrespective of variations in testing locations and personnel.
1. 5-8 study sites will be selected with each site being a recognized NIH Center of
Excellence for Alzheimer's disease or other nationally recognized Alzheimer's disease
research center.
2. Each site will evaluate up to 60 subjects evenly divided between AD patients and
age-matched controls (while the prevalence of AD is approximately 2% in the general
population, the ratio of AD to normal among those who visit a clinic for memory or
cognitive related issues is between 50-60%).
3. Each site will follow the same testing protocols.
4. All test data will be uploaded to the online COGNISION™ database server.
A. Multi-Center Study:
primary goal of this study will be to evaluate the COGNISION™ Platform across multiple study
locations. This will demonstrate an ability to perform tests, collect data, and generate
classifications irrespective of variations in testing locations and personnel.
1. 5-8 study sites will be selected with each site being a recognized NIH Center of
Excellence for Alzheimer's disease or other nationally recognized Alzheimer's disease
research center.
2. Each site will evaluate up to 60 subjects evenly divided between AD patients and
age-matched controls (while the prevalence of AD is approximately 2% in the general
population, the ratio of AD to normal among those who visit a clinic for memory or
cognitive related issues is between 50-60%).
3. Each site will follow the same testing protocols.
4. All test data will be uploaded to the online COGNISION™ database server.
Inclusion Criteria:
AD Cohort:
Subjects between 60 and 90 years old meeting NINCDS-ADRDA criteria for probable AD2 and
DSM-IV criteria for dementia of the Alzheimer's type3 will be recruited in the AD cohort
(MMSE ≥21, ≤26).
Memory complaint by subject and/or study partner SRP-1418 N Page: 8 of 26
Abnormal memory function score on Logical Memory II subscale (Delayed Paragraph Recall)
from the Wechsler Memory Scale - Revised (adjusted for education. Maximum score is 25):
i. < 10 for 16 or more years of education ii. < 6 for 8-15 years of education iii. < 4 for
0-7 years of education Clinical Dementia Rating (CDR) = 0.5, 1.0 or 2.0 Modified Hachinski
Ischemic Scale (HIS) ≤ 4 Geriatric Depression Scale (GDS) < 6 For subjects that decide to
provide a CSF sample: Platelet count ≥ 100,000/μL, Prothrombin Time (PT) = 11 to 16
seconds, International Normalized Ratio = 0.8 to 1.2 Study partner or caregiver to
accompany subject to all scheduled visits Fluent in English Adequate visual acuity to
allow neuropsychological testing Adequate auditory acuity to allow neuropsychological and
ERP testing Good general health with no additional diseases expected to interfere with the
study Willing to undergo neuroimaging and provide blood. The subject may optionally
provide a CSF sample by lumbar puncture.
Normal Controls:
Healthy subjects matched for age, gender, and education level will be recruited as normal
controls (MMSE ≥ 27).
Normal memory function will be documented by scoring at specific cutoffs on the
Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale -
Revised:
i. ≥ 10 for 16 or more years of education ii. ≥ 6 for 8-15 years of education iii. ≥ 4 for
0-7 years of education Study partner or caregiver Fluent in English Adequate visual acuity
to allow neuropsychological testing Adequate auditory acuity to allow neuropsychological
and ERP testing
Exclusion Criteria:
AD Cohort:
Severe or unstable forms of diabetes, heart disease, HIV, drug or alcohol abuse, etc.
including severe AD: MMSE ≤20 Platelet count < 100,000/μL, Prothrombin Time (PT) > 16
seconds, International Normalized Ratio > 1.2 (for subjects that choose to provide a CSF
sample by lumbar puncture).
Medical or psychiatric disorders that might complicate the assessment of dementia (i.e.,
mental retardation, alcohol abuse, drug abuse, HIV) A disability that may prevent the
subject from completing all study requirements (e.g., blindness, deafness, language
difficulty) Recent intake of drugs known to cause major organ system toxicity or CNS
alteration (e.g. sedation) Diseases of the dementia type other than AD (i.e., vascular
dementia, frontotemporal dementia, Lewy Body Disease, Huntington's disease) Presence of
non-MRI compatible implants/devices Prohibited Medications: Warfarin or other
anticoagulants (for subjects that choose to provide a CSF sample by lumbar puncture),
investigational agents.
Normal Controls:
Severe or unstable forms of diabetes, heart disease, HIV, drug or alcohol abuse, etc.
A disability that may prevent the subject from completing all study requirements (e.g.,
blindness, deafness, language difficulty) Use of psychoactive drugs (only SSRI's are
allowed) Psychiatric disorders (schizophrenia, bipolar, etc.) Depression (GDS > 6)
Vascular dementia (HIS > 4) Other dementia (CDR > 0)
Abnormal memory function score on Wechsler Memory Scale -Logical Memory II subscale
(delayed Paragraph Recall) from the Wechsler Memory Scale - Revised (the maximum score is
25):
I. < 10 for 16 or more years of education II. < 6 for 8-15 years of education III. < 4 for
0-7 years of education
We found this trial at
7
sites
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
Click here to add this to my saved trials
Click here to add this to my saved trials
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
Click here to add this to my saved trials